# Clinical Trials Data ALK - Document 17

# Analysis of Plasma Tumor DNA in Lung Cancer Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT01930474

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer\n\* Have molecular evidence of genetic alterations in tumor sample (eg. EGFR mutations, ALK fusions)\n\* Patients must have given written informed consent\n\nExclusion Criteria:\n\n\* Patients who refuse the blood samplings",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "The non-small cell lung cancer patients who will be or have been treated with chemotherapy (including target agents)",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with an ALK gene mutation would be eligible for this clinical trial. The inclusion criteria specifically state "molecular evidence of genetic alterations in tumor sample (eg. EGFR mutations, ALK fusions)". ALK fusions are a type of ALK gene mutation. As long as the patient also meets the other inclusion criteria (confirmed NSCLC diagnosis and provides informed consent) and doesn't meet any exclusion criteria (refusal of blood sampling), they would be eligible.